Covered recipient · General Payments record
JAIME LANDMAN
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$108.04
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $108.04 | 5 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $66.20 | 3 |
| Blueprint Medicines Corporation | $25.20 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.64 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAIME LANDMAN
NPI 1346204690 · CMS profile ID 105508
Allopathic & Osteopathic Physicians / Allergy & Immunology
AVENTURA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346204690?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $108.04 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $21.99 | 12/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002291935 | CMS |
| GlaxoSmithKline, LLC. | $20.21 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002301993 | CMS |
| Blueprint Medicines Corporation | $25.20 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051275301 | CMS |
| GlaxoSmithKline, LLC. | $24.00 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002297157 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.64 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055445323 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $751,515.35 | 131 |
| PY2024 | Principal investigator | $525,143.48 | 126 |
| PY2023 | Principal investigator | $497,961.58 | 102 |
| PY2022 | Principal investigator | $447,451.34 | 86 |
| PY2021 | Principal investigator | $586,667.15 | 102 |
| PY2020 | Recipient | $11,702.26 | 1 |
| PY2020 | Principal investigator | $473,131.41 | 28 |
| PY2019 | Recipient | $1,525.00 | 1 |
| PY2019 | Principal investigator | $615,806.88 | 59 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
29 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,800.50 | 12/31/2020 | Non-covered Recipient Entity Florida Ctr For Allergy And Asthma | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma | No dispute reported | 06/30/2026 | 736743755 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,952.32 | 12/31/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106447 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,611.44 | 12/21/2020 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE | A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S | No dispute reported | 06/30/2026 | 965525753 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $440.01 | 12/11/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106391 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $880.02 | 12/08/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106389 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $880.02 | 11/25/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106387 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 11/24/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106377 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,000.00 | 11/24/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106379 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $880.02 | 11/17/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106385 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $880.02 | 11/11/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106383 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,760.04 | 10/22/2020 | Non-covered Recipient Entity Florida Center For Allergy & Asthma Research | CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | No dispute reported | 06/30/2026 | 740106381 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,350.00 | 10/15/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106433 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,985.00 | 08/14/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106427 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,605.23 | 08/11/2020 | Non-covered Recipient Entity FLORIDA CENTER ALLERGY ASTHMA RESEARCH | A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. | No dispute reported | 06/30/2026 | 721491321 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35,550.00 | 07/23/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106423 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $22,050.00 | 06/22/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106419 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,800.00 | 05/21/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106415 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $20,250.00 | 04/27/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106405 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 04/27/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106407 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,650.00 | 04/22/2020 | Non-covered Recipient Entity Florida Ctr For Allergy And Asthma | A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 736747879 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,450.00 | 03/18/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106401 |
| Principal investigator 1 | Eli Lilly and Company | $281,132.00 | 03/17/2020 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | No dispute reported | 06/30/2026 | 728742319 |
| Principal investigator 1 | Eli Lilly and Company | $55.89 | 03/06/2020 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | No dispute reported | 06/30/2026 | 728736279 |
| Recipient | Eli Lilly and Company | $11,702.26 | 02/25/2020 | Covered Recipient Physician | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | No dispute reported | 06/30/2026 | 728720489 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,000.00 | 02/24/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106397 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,447.50 | 02/18/2020 | Non-covered Recipient Entity Florida Ctr For Allergy And Asthma | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma | No dispute reported | 06/30/2026 | 736749697 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,515.00 | 01/29/2020 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | No dispute reported | 06/30/2026 | 721491327 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,900.00 | 01/28/2020 | Non-covered Recipient Entity Florida Center for Allergy and Asthma Research | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 740106393 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,306.40 | 01/01/2020 | Non-covered Recipient Entity FLORIDA CENTER ALLERGY ASTHMA RESEARCH | A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD OF CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 721491325 |